Copeptin and insulin

Copeptin and insulin-like growth factor binding protein-1 analysed at admission for a myocardial infarction in patients with type 2 diabetes mellitus predicts cardiovascular events. The present aim was to study the association between copeptin and insulin-like growth factor binding protein-1, the development of the levels over time, and if the predictive value remained when measured at hospital discharge and 3？months thereafter. Copeptin and insulin-like growth factor binding protein-1 were analysed in patients (median age？=？70, male？=？68%) with type 2 diabetes mellitus？+？myocardial infarction at admission (n？=？393), discharge (n？=？309) and 3？months later (n？=？288). The primary endpoint was cardiovascular event (cardiovascular death/non-fatal myocardial infarction/stroke) with the three time points as separate baselines. The median copeptin levels were 21.8？pmol/L at admission, 8.5？pmol/L at discharge and 8.4？pmol/L after 3？months, while insulin-like growth factor binding protein-1 levels continued to increase. There were significant correlations between the biomarkers at all occasions. During an average follow-up of 2.5？years, copeptin, but not insulin-like growth factor binding protein-1, predicted cardiovascular event at all occasions in unadjusted analyses. Copeptin remained as a predictor at discharge and after 3？months in the final multiple model (including: heart failure/age/creatinine clearance). The relationship between copeptin and insulin-like growth factor binding protein-1 during the initial phase of a myocardial infarction persisted in a less-stressful situation, and copeptin remained as a prognostic indicator at discharge and 3？months later